Medoc, a provider of neuro-diagnostic medical systems, has announced its official expansion from supporting academic research to serving the needs of Clinical Research Organizations, yielding improved success probabilities of pharmaceutical clinical trials.
Medoc's products provide neuro-diagnostic testing of small sensory nerve fibers and pain mechanisms using Quantitative Sensory Testing (QST) and Contact Heat Evoked Potential (CHEPs) techniques.
The company's devices have been utilized and integrated into all phases of clinical trials. In Phase I studies, Medoc devices are used to assess analgesic effects based on subjects' responses to experimental pain models. These are used to produce first-in-human early efficacy measures. Medoc devices are also commonly used in both Phase II and III studies to phenotype subjects for either inclusion or sub-grouping based on specific characteristics as a predictor of treatment response.
Implementing Medoc capabilities in Phase I and II trials contributes significantly to the development of an optimal, robust study design for the pivotal trials, maximizing the chances that they will succeed.
With its expansion into the pharmaceutical sphere, Medoc now offers tailored solutions to accommodate the specific needs and requirements of pharma and CROs including: research and development supporting early design phases, recommendations for advanced QST test batteries and trial end-points, software customized to trial-specific protocols as well as data collection methods, training and support.
Medoc's testing devices are streamlined, plug & play solutions without time-consuming set-up procedures or complex operation.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.